FDA approves first interchangeable biosimilar insulin product
The Food and Drug Administration this week approved the first interchangeable biosimilar insulin product to treat diabetes. The product (Semglee) can be substituted for the previously approved biological insulin product Lantus to treat type 1 diabetes in children and type 1 or 2 diabetes in adults.
“This is a momentous day for people who rely daily on insulin for treatment of diabetes, as biosimilar and interchangeable biosimilar products have the potential to greatly reduce health care costs,” said Acting FDA Commissioner Janet Woodcock, M.D.
For more information on biosimilar and interchangeable products, see the new FDA resources for health care providers.
Related News Articles
Headline
Sarah Stella, M.D., director of Denver Health’s Housing Outreach, Partnerships and Engagement program, or HOPE, reveals how Denver Health is helping some of…
Headline
The AHA is launching a new learning collaborative, Adopting Digital Tools for Better Aging Care, which is part of the West Health Accelerator at AHA’s Health…
Headline
The Centers for Disease Control and Prevention will host a webinar for clinicians May 28 at 2 p.m. ET on the ongoing Ebola outbreak in the Democratic…
Headline
The convening of 600 leaders from hospitals, health systems, and community and public health organizations continued for a full-day schedule at the AHA…
Headline
The Department of Health and Human Services Administration for Community Living has launched the first phase of its Health at Home Challenge, a competition to…
Headline
The Centers for Disease Control and Prevention released a Health Alert Network Health Advisory May 8 notifying clinicians and health departments of the…